Androgen ablation therapy--where to next?

Editorial

J Trachtenberg. J Urol. 1997 Jul.

. 1997 Jul;158(1):178.

doi: 10.1097/00005392-199707000-00057.

No abstract available

Comment on

Long-term efficacy and safety of nilutamide plus castration in advanced prostate cancer, and the significance of early prostate specific antigen normalization. International Anandron Study Group.
Dijkman GA, Janknegt RA, De Reijke TM, Debruyne FM. Dijkman GA, et al. J Urol. 1997 Jul;158(1):160-3. doi: 10.1097/00005392-199707000-00051. J Urol. 1997. PMID: 9186345 Clinical Trial.
Prognostic factors in patients with metastatic (stage D2) prostate cancer: experience from the Scandinavian Prostatic Cancer Group Study-2.
Jørgensen T, Kanagasingam Y, Kaalhus O, Tveter KJ, Bryne M, Skjørten F, Berner A, Danielsen HE. Jørgensen T, et al. J Urol. 1997 Jul;158(1):164-70. doi: 10.1097/00005392-199707000-00052. J Urol. 1997. PMID: 9186346 Clinical Trial.
The prognostic value of neuroendocrine differentiation in adenocarcinoma of the prostate in relation to progression of disease after endocrine therapy.
Krijnen JL, Bogdanowicz JF, Seldenrijk CA, Mulder PG, van der Kwast TH. Krijnen JL, et al. J Urol. 1997 Jul;158(1):171-4. doi: 10.1097/00005392-199707000-00054. J Urol. 1997. PMID: 9186347
Is prednisolone as good as flutamide in hormone refractory metastatic carcinoma of the prostate?
Datta SN, Thomas K, Matthews PN. Datta SN, et al. J Urol. 1997 Jul;158(1):175-7. doi: 10.1097/00005392-199707000-00056. J Urol. 1997. PMID: 9186348 Clinical Trial.